Sanofi (SAN) Received a €90.00 Target Price by Jefferies Financial Group Analysts

Sanofi (SAN) Received a €90.00 Target Price by Jefferies Financial Group Analysts

Sanofi (EPA:SAN) has been given a €90.00 ($104.65) price objective by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the stock.

Several other research firms have also issued reports on SAN. Barclays set a €80.00 ($93.02) price objective on shares of Sanofi and gave the stock a “neutral” rating in a research report on Thursday, November 1st. Societe Generale set a €94.00 ($109.30) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Thursday, November 1st. Credit Suisse Group set a €82.00 ($95.35) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Thursday, November 1st. Cfra set a €87.00 ($101.16) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Thursday, November 1st. Finally, Deutsche Bank set a €87.00 ($101.16) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Thursday, November 1st. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of €84.75 ($98.55).

Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Day Trading – Risk Worth the Reward?

Related posts

Leave a Comment